Vanguard Personalized Indexing Management LLC Acquires New Shares in Supernus Pharmaceuticals, Inc. $SUPN

Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,491 shares of the specialty pharmaceutical company's stock, valued at approximately $205,000.

A number of other hedge funds have also recently made changes to their positions in the company. Armistice Capital LLC boosted its stake in shares of Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after purchasing an additional 360,000 shares in the last quarter. GW&K Investment Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after purchasing an additional 176,091 shares in the last quarter. Ashford Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 3.8% during the first quarter. Ashford Capital Management Inc. now owns 566,556 shares of the specialty pharmaceutical company's stock valued at $18,555,000 after purchasing an additional 20,781 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 4.4% during the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company's stock valued at $17,378,000 after purchasing an additional 22,562 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after purchasing an additional 9,590 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SUPN shares. Piper Sandler raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. TD Cowen lifted their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Saturday. Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Finally, Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Buy" and an average price target of $62.67.

Supernus Pharmaceuticals Stock Up 1.6%

NASDAQ SUPN opened at $52.83 on Friday. The company has a market cap of $2.96 billion, a price-to-earnings ratio of 45.94 and a beta of 0.78. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $53.28. The business has a 50 day moving average price of $46.87 and a 200-day moving average price of $37.97.

Insider Buying and Selling

In related news, Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the transaction, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $689,726.96. The trade was a 47.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 362,741 shares of company stock worth $16,390,592 in the last ninety days. Corporate insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.